Fiche publication
Date publication
mars 2022
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Dr CHAIGNEAU Loïc
,
Dr MENEVEAU Nathalie
,
Pr PIVOT Xavier
,
Pr PRETET Jean-Luc
,
Dr CURTIT Elsa
,
Dr MANSI Laura
,
Pr FEUGEAS Jean-Paul
,
Dr SELMANI Zohair
,
Dr MOLIMARD Chloé
Tous les auteurs :
Selmani Z, Molimard C, Overs A, Bazan F, Chaigneau L, Dobi E, Meneveau N, Mansi L, Paillard MJ, Meynard G, Viot J, Algros MP, Borg C, Feugeas JP, Pivot X, Prétet JL, Curtit E
Lien Pubmed
Résumé
Breast cancers expressing high levels of Ki67 are associated with poor outcomes. Oncotype DX test was designed for ER+/HER2- early-stage breast cancers to help adjuvant chemotherapy decision by providing a Recurrent Score (RS). RS measures the expression of 21 specific genes from tumor tissue, including Ki67. The primary aim of this study was to assess the agreement between Ki67 obtained with Oncotype DX RS and Ki67. Other objectives were to analyze the association between the event free survival (EFS) and the expression level of Ki67; and association between RS and Ki67. Herein, we report a low agreement of 0.288 by Pearson correlation coefficient test between Ki67 and Ki67 in a cohort of 98 patients with early ER+/HER2- breast cancers. Moreover, Ki67 tumors were significantly associated with the occurrence of events (p = 0.03). On the other hand, we did not find any association between Ki67 and EFS (p = 0.26). We observed a low agreement between expression level of Ki67 and Ki67 protein labelling by IHC. Unlike Ki67 and independently of the RS, Ki67 could have a prognostic value. It would be interesting to better assess the prognosis and predictive value of Ki67 measured by qRT-PCR. The Ki67 in medical routine could be a good support in countries where Oncotype DX is not accessible.
Référence
Sci Rep. 2022 Mar 7;12(1):3617
